Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (101-110 of 276) with videos related to

Pageof 28
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
BJU International|July 31, 2003
Putative protein markers in the sera of men with prostatic neoplasmsS Lehrer, J Roboz, H Ding, et al.
Blood Advances|April 14, 2022
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101Ellen K Ritchie, Heidi D Klepin, Elizabeth Storrick, et al.
Blood Advances|November 27, 2024
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance)Catherine Lai, Minji Lee, Olivia Bobek, et al.
Leukemia & Lymphoma|August 20, 2020
Updated safety of midostaurin plus chemotherapy in newly diagnosed <i>FLT3</i> mutation-positive acute myeloid leukemia: the RADIUS-X expanded access programGail J Roboz, Stephen A Strickland, Mark R Litzow, et al.
Leukemia Research|May 4, 2007
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz, John M Bennett, Morton Coleman, et al.
Neoplasia (New York, N.Y.)|May 26, 2019
Telomere Trimming and DNA Damage as Signatures of High Risk NeuroblastomaEun Young Yu, Irene Y Cheung, Yi Feng, et al.
Leukemia|March 24, 2021
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerationsRoland B Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Leukemia & Lymphoma|August 11, 2017
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemiaNicole M Cruz, Mayumi Sugita, Nathan Ewing-Crystal, et al.
Leukemia Research|October 20, 2010
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndromeGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Pageof 28

Showing results (101-110 of 276) with videos related to

Sort By:
Pageof 28
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 26, 2006
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore, John Harpel, Michael W Schuster, et al.
BJU International|July 31, 2003
Putative protein markers in the sera of men with prostatic neoplasmsS Lehrer, J Roboz, H Ding, et al.
Blood Advances|April 14, 2022
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101Ellen K Ritchie, Heidi D Klepin, Elizabeth Storrick, et al.
Blood Advances|November 27, 2024
Deficit accumulation frailty index and treatment tolerability in AML: data from CALGB 11001 and 11002 (Alliance)Catherine Lai, Minji Lee, Olivia Bobek, et al.
Leukemia & Lymphoma|August 20, 2020
Updated safety of midostaurin plus chemotherapy in newly diagnosed <i>FLT3</i> mutation-positive acute myeloid leukemia: the RADIUS-X expanded access programGail J Roboz, Stephen A Strickland, Mark R Litzow, et al.
Leukemia Research|May 4, 2007
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphomaGail J Roboz, John M Bennett, Morton Coleman, et al.
Neoplasia (New York, N.Y.)|May 26, 2019
Telomere Trimming and DNA Damage as Signatures of High Risk NeuroblastomaEun Young Yu, Irene Y Cheung, Yi Feng, et al.
Leukemia|March 24, 2021
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerationsRoland B Walter, Yishai Ofran, Agnieszka Wierzbowska, et al.
Leukemia & Lymphoma|August 11, 2017
Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemiaNicole M Cruz, Mayumi Sugita, Nathan Ewing-Crystal, et al.
Leukemia Research|October 20, 2010
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndromeGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Pageof 28